Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D6NQ
|
|||
| Former ID |
DIB005962
|
|||
| Drug Name |
HEV-239
|
|||
| Synonyms |
Hecolin; Bacterially-expressed hepatitis E vaccine, Xiamen Innovax Biotech; Hepatitis E vaccine (recombinant), Xiamen Innovax Biotech; Hepatitis E vaccine (alum-adjuvanted), Xiamen Innovax Biotech
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Hepatitis E virus infection [ICD-11: 1E50.4] | Approved | [1], [2] | |
| Company |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell mediated immunity response (CMIR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02189603) Phase Clinical Trial of Recombinant Hepatitis E Vaccine ecolin . U.S. National Institutes of Health. | |||
| REF 2 | The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.